Craft

Amoy Diagnostics

Stock Price

¥24.9

2023-09-28

Market Capitalization

¥9.9 B

2023-09-28

Revenue

¥828.7 M

FY, 2022

Amoy Diagnostics Summary

Company Summary

Overview
Amoy Diagnostics (AmoyDx, 厦门艾德生物医药科技股份有限公司) is a company that provides molecular diagnostic products and services for oncology precision medicine. It uses technology platforms including next-generation sequencing (NGS), polymerase chain reaction (PCR), and fluorescence in situ hybridization (FISH) to provide single gene testing kits, multi-gene testing panels, NGS panels, and NGS analytical systems. The company serves healthcare providers, academic institutions, and pharmaceutical businesses.
Type
Public
Status
Active
Founded
2008
HQ
Xiamen, CN | view all locations
Website
https://amoydiagnostics.com/
Cybersecurity rating
ESG rating
30-39 out of 100|View all ESG data
Sectors

Key People

  • Li-Mou Zheng, Chairman

    • Frank Ron Zheng, Director and Deputy General manager

      • David Guowei Wang, Director

        Operating MetricsView all

        Patents (Domestic)

        55
        22.2%

        H1, 2022

        Medical Device Registration Certificates

        24
        4.3%

        H1, 2022

        Medical Institutions Covered

        500

        H1, 2022

        LocationsView all

        1 location detected

        • Xiamen, Fujian Sheng HQ

          China

          39 Dingshan Road, Haicang District

        Amoy Diagnostics Financials

        Summary Financials

        Revenue (Q2, 2023)
        ¥257.3M
        Gross profit (Q2, 2023)
        ¥218.6M
        Net income (Q2, 2023)
        ¥69.4M
        Cash (Q2, 2023)
        ¥227.5M
        EBIT (Q2, 2023)
        ¥57.6M
        Enterprise value
        $9.7B

        Footer menu